China's Five-Year Plan Targets Off-the-Shelf Cell Therapy
China's Document No. 210 (September 18, 2026) names off-the-shelf cell therapy a breakthrough target in its 2026-2030 medical industry plan alongside xenotransplantation and organ engineering, with a medical industry revenue target of at least 3.5 trillion yuan (~$523B).
On September 18, 2026, ten Chinese government agencies led by the Ministry of Industry and Information Technology published Document No. 210, a plan for China's medical industry from 2026 to 2030. The document calls for technological breakthroughs in several areas. Among them: universal cell therapy using off-the-shelf cell products.
The same list includes xenotransplantation (transplanting animal organs into humans), construction of complex organs capable of regeneration, and synthesis of artificial living systems (assembling functioning biological systems from scratch). Separately, the plan targets expanded work on genome editing and next-generation brain-computer interfaces. For rare diseases (hemophilia, amyotrophic lateral sclerosis, Gaucher disease), it calls for accelerated development and clinical use of cell and gene therapy.
The plan builds on the previous cycle: during 2021 to 2025, China brought 230 new drugs to market and rose to second place globally in the number of drugs under development. By the end of 2025, 323.38 million residents were aged 60 and older (23% of the population); the ministry's explanatory note explicitly ties the new cycle to population aging. In the section on traditional Chinese medicine, anti-aging products are singled out as a new consumer category.
The plan targets medical industry revenue of at least 3.5 trillion yuan (roughly $523 billion). It also calls for at least one quarter of all first-in-class drugs worldwide (drugs with a novel mechanism of action) to be Chinese. In the first half of 2026 alone, licensing deals between Chinese and foreign pharma companies for new drugs reached $106.3 billion (the full-year 2025 total was $135.7 billion).
The document lists cell therapy among its priority areas. The 3.5 trillion yuan revenue target covers the medical industry as a whole. Our source materials include no clinical data on specific off-the-shelf cell products.
Open the Cell Therapy term page on Eternal Search
Sources
[1] miit.gov.cn
[2] miit.gov.cn
[3] stats.gov.cn
[4] finance.biggo.com
Document No. 210 names off-the-shelf cell therapy as a required breakthrough alongside xenotransplantation and organ engineering, creating a concrete policy hook to introduce the Cell Therapy term page on Eternal Search. The news item lets us explain precisely which capability China is prioritizing within a broad government document, and the term page gives readers the foundational context to assess what that priority actually means without overstating what an industrial plan proves about clinical outcomes.